JP2019519581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519581A5 JP2019519581A5 JP2018568426A JP2018568426A JP2019519581A5 JP 2019519581 A5 JP2019519581 A5 JP 2019519581A5 JP 2018568426 A JP2018568426 A JP 2018568426A JP 2018568426 A JP2018568426 A JP 2018568426A JP 2019519581 A5 JP2019519581 A5 JP 2019519581A5
- Authority
- JP
- Japan
- Prior art keywords
- solid oral
- modified release
- release solid
- oral formulation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 claims 49
- 239000000203 mixture Substances 0.000 claims 44
- 238000009472 formulation Methods 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 14
- 238000002360 preparation method Methods 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000002702 enteric coating Substances 0.000 claims 7
- 238000009505 enteric coating Methods 0.000 claims 7
- 239000010410 layer Substances 0.000 claims 7
- 239000006186 oral dosage form Substances 0.000 claims 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 5
- 239000011247 coating layer Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229920001519 homopolymer Polymers 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 5
- 238000009498 subcoating Methods 0.000 claims 5
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 4
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 229920002678 cellulose Chemical class 0.000 claims 4
- 239000001913 cellulose Chemical class 0.000 claims 4
- 235000010980 cellulose Nutrition 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 206010043207 temporal arteritis Diseases 0.000 claims 3
- ISBHMJZRKAFTGE-ONEGZZNKSA-N (e)-pent-2-enenitrile Chemical compound CC\C=C\C#N ISBHMJZRKAFTGE-ONEGZZNKSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 229920003134 Eudragit® polymer Polymers 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 claims 1
- LCFFREMLXLZNHE-RUZDIDTESA-N 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound CC(C)(C=C(C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1 LCFFREMLXLZNHE-RUZDIDTESA-N 0.000 claims 1
- LCFFREMLXLZNHE-VWLOTQADSA-N 2-[(3s)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound C12=C(N)N=CN=C2N([C@H]2CCCN(C2)C(=O)C(C#N)=CC(C)(C)N2CCN(CC2)C2COC2)N=C1C(C(=C1)F)=CC=C1OC1=CC=CC=C1 LCFFREMLXLZNHE-VWLOTQADSA-N 0.000 claims 1
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims 1
- 208000008822 Ankylosis Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- MWAPCVRIQHXPBI-UHFFFAOYSA-N CC(C=CC#N)(C)N1CCN(CC1)C1COC1 Chemical compound CC(C=CC#N)(C)N1CCN(CC1)C1COC1 MWAPCVRIQHXPBI-UHFFFAOYSA-N 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010023198 Joint ankylosis Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000002740 Muscle Rigidity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010071579 Neuronal neuropathy Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 206010003882 axonal neuropathy Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 125000005591 trimellitate group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356345P | 2016-06-29 | 2016-06-29 | |
| US62/356,345 | 2016-06-29 | ||
| PCT/US2017/040075 WO2018005849A1 (en) | 2016-06-29 | 2017-06-29 | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519581A JP2019519581A (ja) | 2019-07-11 |
| JP2019519581A5 true JP2019519581A5 (enExample) | 2020-08-13 |
| JP7129704B2 JP7129704B2 (ja) | 2022-09-02 |
Family
ID=59315766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568426A Active JP7129704B2 (ja) | 2016-06-29 | 2017-06-29 | ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペント－２－エネニトリルの放出調節製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20190231784A1 (enExample) |
| EP (1) | EP3478273A1 (enExample) |
| JP (1) | JP7129704B2 (enExample) |
| KR (2) | KR102515813B1 (enExample) |
| CN (2) | CN109600989B (enExample) |
| AU (2) | AU2017290354C1 (enExample) |
| CA (1) | CA3028169C (enExample) |
| EA (1) | EA201892836A1 (enExample) |
| IL (2) | IL293621B2 (enExample) |
| MA (1) | MA45547A (enExample) |
| MX (2) | MX390619B (enExample) |
| SG (1) | SG11201811255WA (enExample) |
| WO (1) | WO2018005849A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266895B2 (en) | 2012-09-10 | 2016-02-23 | Principia Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors |
| EP4681737A3 (en) | 2014-02-21 | 2026-03-11 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| US12187710B2 (en) | 2018-12-14 | 2025-01-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salt of Syk inhibitor and crystalline form thereof |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| AU2020363873A1 (en) | 2019-10-09 | 2022-04-14 | Principia Biopharma Inc. | Methods of treating pemphigus by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| JP7795454B2 (ja) | 2019-10-14 | 2026-01-07 | プリンシピア バイオファーマ インコーポレイテッド | （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法 |
| JP7702409B2 (ja) * | 2020-01-06 | 2025-07-03 | プリンシピア バイオファーマ インコーポレイテッド | ＢＴＫ阻害剤２－［（３Ｒ）－３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを使用する、膜性腎症、ＩＧＧ４関連疾患、及び抗リン脂質症候群の処置 |
| AU2021205248A1 (en) * | 2020-01-08 | 2022-09-01 | Principia Biopharma Inc. | Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile |
| AU2021209884A1 (en) | 2020-01-22 | 2022-09-15 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2022033460A1 (zh) * | 2020-08-10 | 2022-02-17 | 江苏恒瑞医药股份有限公司 | Btk抑制剂治疗疾病的用途 |
| CN116157404B (zh) | 2020-08-14 | 2025-10-14 | 诺华股份有限公司 | 杂芳基取代的螺哌啶基衍生物及其药物用途 |
| AU2022257016A1 (en) | 2021-04-16 | 2023-11-30 | Principia Biopharma, Inc. | Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds |
| US20260000620A1 (en) * | 2022-01-13 | 2026-01-01 | Amryt Endo, Inc. | Oral dosage forms |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| TW202432135A (zh) | 2022-10-31 | 2024-08-16 | 美商普林斯匹亞生物製藥公司 | 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－氧雜環丁－３－基）哌𠯤－１－基］戊－２－烯腈治療免疫性血小板減少症的方法 |
| KR20250114128A (ko) | 2022-12-09 | 2025-07-28 | 프린시피아 바이오파마, 인코퍼레이티드 | 인지 장애가 있는 대상체의 면역성 혈소판감소증을 릴자브루티닙 투여로 치료하는 방법 |
| EP4735001A1 (en) | 2023-06-30 | 2026-05-06 | Principia Biopharma Inc. | Methods for treating persistent or chronic immune thrombocytopenia in children, adolescents and adults by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4- methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| CN121368486A (zh) | 2023-07-17 | 2026-01-20 | 卡德门企业有限公司 | 包含btk抑制剂和贝舒地尔的组合疗法 |
| WO2025090702A1 (en) | 2023-10-25 | 2025-05-01 | Principia Biopharma Inc. | Rilzabrutinib for use in the treatment of itch associated with atopic dermatitis and/or prurigo nodularis |
| TW202539683A (zh) | 2023-12-06 | 2025-10-16 | 美商普林斯匹亞生物製藥公司 | 透過投予（ｒ）－２［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療中度至重度氣喘 |
| TW202602449A (zh) * | 2024-03-19 | 2026-01-16 | 美商普林斯匹亞生物製藥公司 | ２－［（３ｒ）－２－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４［４－（氧雜環丁烷－３－基）哌－１－基］－戊－２－烯腈的調配物 |
| WO2026024765A1 (en) | 2024-07-23 | 2026-01-29 | Principia Biopharma Inc. | Treatment of venous thrombosis with rilzabrutinib and derivatives thereof |
| WO2026024885A1 (en) | 2024-07-24 | 2026-01-29 | Principia Biopharma Inc. | Rilzabrutinib for treating warm antibody autoimmune hemolytic anemia |
| WO2026035812A1 (en) | 2024-08-08 | 2026-02-12 | Principia Biopharma Inc. | Methods for treating sickle cell disease by administering a btk inhibitor |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| JPS5663950A (en) | 1979-10-30 | 1981-05-30 | Mitsubishi Chem Ind Ltd | Cyclopropanecarboxylic ester |
| FR2535721A1 (fr) | 1982-11-08 | 1984-05-11 | Sanofi Sa | Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives |
| JPH021450Y2 (enExample) | 1984-09-27 | 1990-01-16 | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| JP2518353B2 (ja) | 1988-06-09 | 1996-07-24 | 住友化学工業株式会社 | シアノ酢酸アミド誘導体およびその製造中間体 |
| CA2018801C (en) | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus |
| JPH04177244A (ja) | 1990-11-10 | 1992-06-24 | Konica Corp | ハロゲン化銀写真感光材料 |
| CA2033447C (en) | 1990-12-31 | 1999-08-31 | Robert Deziel | Synergistic combination for treating herpes infections |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JPH05301838A (ja) | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| JPH0827090A (ja) | 1994-05-13 | 1996-01-30 | Sumitomo Chem Co Ltd | シアノ酢酸アミド誘導体、その用途およびその製造中間体 |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| EP0970044B1 (de) | 1997-03-14 | 2003-05-07 | Basf Aktiengesellschaft | Cycloalkylalkancarbonsäureamide, deren herstellung und verwendung |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| IL125947A0 (en) | 1997-09-17 | 1999-04-11 | American Cyanamid Co | 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents |
| BR9815240A (pt) | 1997-10-09 | 2001-10-30 | Perio Prod Ltd | Sistema de fornecimento de medicamentogastrointestinal de liberação total retardada |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| NZ513639A (en) | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| KR20020088406A (ko) | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| EP1451173A4 (en) | 2001-11-01 | 2005-10-26 | Icagen Inc | PIPERIDINE |
| JP3991812B2 (ja) | 2001-12-11 | 2007-10-17 | 住友化学株式会社 | エステル化合物およびその用途 |
| AU2003210983A1 (en) | 2002-02-11 | 2003-09-04 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
| GB0219024D0 (en) | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| JP3955523B2 (ja) | 2002-11-27 | 2007-08-08 | 日立建機株式会社 | 垂直度計および多段伸縮式アーム作業機 |
| CA2516234A1 (en) | 2003-02-21 | 2004-09-02 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| JP4727579B2 (ja) | 2003-08-01 | 2011-07-20 | 中外製薬株式会社 | マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なシアノアミド化合物 |
| KR20090080143A (ko) | 2003-09-02 | 2009-07-23 | 화이자 프로덕츠 인크. | 지프라시돈의 지속 방출형 투여 형태 |
| WO2005023773A1 (en) | 2003-09-04 | 2005-03-17 | Pfizer Limited | Process for the preparation of substituted aryl pyrazoles |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| RU2344121C2 (ru) | 2003-09-25 | 2009-01-20 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Способы лечения заболеваний у млекопитающих |
| CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| JP4552456B2 (ja) | 2004-02-27 | 2010-09-29 | 住友化学株式会社 | エステル化合物およびその用途 |
| JPWO2005085210A1 (ja) | 2004-03-10 | 2008-01-17 | 小野薬品工業株式会社 | ニトリル化合物およびその化合物を有効成分として含有する医薬組成物 |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| US7807719B2 (en) | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
| US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| EP1846405A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
| CA2603105A1 (en) | 2005-03-28 | 2006-10-05 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
| BRPI0611187A2 (pt) | 2005-06-03 | 2010-08-24 | Xenon Pharmaceuticals Inc | derivados aminotiazàis como inibidores da estearoil-coa desaturase humana |
| US20070149464A1 (en) | 2005-06-15 | 2007-06-28 | Pfizer Inc. | Combination |
| US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
| US20080176865A1 (en) | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
| US20080146643A1 (en) | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
| ES2338699T3 (es) | 2005-06-15 | 2010-05-11 | Pfizer Limited | Arilpirazoles sustituidos para uso contra parasitos. |
| GB0517205D0 (en) * | 2005-08-22 | 2005-09-28 | Novartis Ag | Organic compounds |
| EP1932833B1 (en) | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| US8338594B2 (en) | 2005-12-02 | 2012-12-25 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| BRPI0621027A2 (pt) | 2006-01-13 | 2011-11-29 | Pharmacyclics Inc | composto, composição farmacêutica |
| PL2514742T3 (pl) | 2006-03-31 | 2015-07-31 | Univ Texas | Leki przeciwnowotworowe będące pochodnymi kwasu kawowego dostępnymi biologicznie po podaniu doustnym |
| US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| EP2029597A4 (en) | 2006-05-31 | 2011-11-23 | Univ California | purine analogs |
| US20100292229A1 (en) | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| WO2008006032A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| PL2526933T3 (pl) | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| ES2403546T3 (es) | 2006-11-03 | 2013-05-20 | Pharmacyclics, Inc. | Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización |
| WO2008061740A1 (en) | 2006-11-23 | 2008-05-29 | Novartis Ag | Pyrimidines and their use as cxcr2 receptor antagonists |
| JP2010522241A (ja) | 2007-03-21 | 2010-07-01 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物 |
| GB2447933A (en) | 2007-03-27 | 2008-10-01 | Chemence Ltd | Cyanoacrylate monomer for forming an adhesive polymer |
| SG10201508035TA (en) | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| KR101261514B1 (ko) | 2008-02-25 | 2013-05-07 | 에프. 호프만-라 로슈 아게 | 피롤로피라진 키나아제 저해제 |
| ATE522536T1 (de) | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
| EP2300469B1 (en) | 2008-05-13 | 2015-06-24 | Novartis AG | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| US8691838B2 (en) | 2008-05-22 | 2014-04-08 | Amgen Inc. | Heterocycles as protein kinase inhibitors |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| EP2324020A2 (en) | 2008-08-01 | 2011-05-25 | Biocryst Pharmaceuticals, Inc. | Piperidine derivatives as jak3 inhibitors |
| US8450337B2 (en) | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
| US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
| US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| RU2595718C2 (ru) | 2009-09-09 | 2016-08-27 | Селджен Авиломикс Рисерч,Инк. | Ингибиторы pi3-киназы и их применение |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| MX2012005678A (es) | 2009-11-16 | 2012-09-07 | Univ California | Enhibidores de cinasas. |
| BR112012029437A2 (pt) | 2010-05-20 | 2017-03-07 | F Hoffmann - La Roche Ag | derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk |
| MX2012013622A (es) | 2010-05-31 | 2013-02-01 | Ono Pharmaceutical Co | Derivado de purinona. |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| CN101880243A (zh) | 2010-06-04 | 2010-11-10 | 贵阳柏丝特化工有限公司 | 一种含氟氰拟除虫菊酯化合物及其合成方法与用途 |
| CN105566229A (zh) | 2010-08-10 | 2016-05-11 | 西建阿维拉米斯研究公司 | Btk抑制剂的苯磺酸盐及其用途和制备方法 |
| SG10201508958WA (en) | 2010-11-01 | 2015-11-27 | Celgene Avilomics Res Inc | Heterocyclic Compounds And Uses Thereof |
| WO2012158810A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EA025496B1 (ru) | 2011-05-17 | 2016-12-30 | Принсипиа Биофарма Инк. | Ингибиторы тирозинкиназы |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| HUE048834T2 (hu) | 2011-05-17 | 2020-08-28 | Univ California | Kináz inhibitorok |
| US8828426B2 (en) * | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
| BR112013033534A2 (pt) | 2011-06-28 | 2017-02-07 | Pharmacyclics Inc | métodos e composições para inibição de reabsorção de osso |
| EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| JP2014522860A (ja) | 2011-07-19 | 2014-09-08 | メルク・シャープ・アンド・ドーム・ベー・フェー | Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド |
| AU2012285987C1 (en) | 2011-07-19 | 2016-09-08 | Merck Sharp & Dohme B.V. | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as Btk- inhibitors |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US20140323504A1 (en) | 2011-09-20 | 2014-10-30 | Cellzome Limited | Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors |
| CN110801454A (zh) | 2011-10-19 | 2020-02-18 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的用途 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| WO2013184572A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| EP2858500A4 (en) | 2012-06-08 | 2016-04-06 | Biogen Ma Inc | BRUTON TYROSINE KINASE HEMMER |
| DK2861599T3 (da) | 2012-06-18 | 2020-03-02 | Principia Biopharma Inc | Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| JP2015522653A (ja) * | 2012-07-26 | 2015-08-06 | ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | プロトンポンプ阻害剤の医薬組成物 |
| WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| US9266895B2 (en) * | 2012-09-10 | 2016-02-23 | Principia Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors |
| EP2914263A4 (en) | 2012-11-02 | 2016-04-27 | Pharmacyclics Inc | ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR |
| CN105008344B (zh) | 2012-11-02 | 2017-07-25 | 辉瑞公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| SG11201503842PA (en) | 2012-11-15 | 2015-06-29 | Pharmacyclics Inc | Pyrrolopyrimidine compounds as kinase inhibitors |
| US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| KR20150099588A (ko) | 2012-12-20 | 2015-08-31 | 더 펜 스테이트 리서어치 파운데이션 | 암의 치료와 관련된 방법 및 조성물 |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US20160113913A1 (en) | 2013-04-19 | 2016-04-28 | Takeda Pharmaceutical Company Limited | Controlled-release drug formulation |
| CN105916859A (zh) | 2014-02-03 | 2016-08-31 | 卡迪拉保健有限公司 | 杂环化合物 |
| EP4681737A3 (en) | 2014-02-21 | 2026-03-11 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| EP3236953B1 (en) | 2014-12-24 | 2020-11-11 | Principia Biopharma Inc. | Site specific dosing of a btk inhibitor |
| FI3236943T3 (fi) | 2014-12-24 | 2023-04-27 | Principia Biopharma Inc | Koostumuksia ileo-jejunaaliseen lääkkeenantoon |
| EP3303334B1 (en) | 2015-06-03 | 2021-06-02 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| WO2017066014A1 (en) | 2015-10-14 | 2017-04-20 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
| IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
| EP3789040A4 (en) | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
| CN110483521B (zh) | 2018-05-14 | 2022-06-07 | 杭州和正医药有限公司 | 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用 |
| JP7795454B2 (ja) | 2019-10-14 | 2026-01-07 | プリンシピア バイオファーマ インコーポレイテッド | （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法 |
| AU2021209884A1 (en) | 2020-01-22 | 2022-09-15 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2022081512A1 (en) | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
-
2017
- 2017-06-29 IL IL293621A patent/IL293621B2/en unknown
- 2017-06-29 SG SG11201811255WA patent/SG11201811255WA/en unknown
- 2017-06-29 CN CN201780049475.1A patent/CN109600989B/zh active Active
- 2017-06-29 EA EA201892836A patent/EA201892836A1/ru unknown
- 2017-06-29 EP EP17738009.4A patent/EP3478273A1/en active Pending
- 2017-06-29 US US16/312,258 patent/US20190231784A1/en not_active Abandoned
- 2017-06-29 MX MX2018016056A patent/MX390619B/es unknown
- 2017-06-29 AU AU2017290354A patent/AU2017290354C1/en active Active
- 2017-06-29 JP JP2018568426A patent/JP7129704B2/ja active Active
- 2017-06-29 CA CA3028169A patent/CA3028169C/en active Active
- 2017-06-29 IL IL263815A patent/IL263815B/en unknown
- 2017-06-29 KR KR1020227013784A patent/KR102515813B1/ko active Active
- 2017-06-29 KR KR1020197002895A patent/KR102391693B1/ko active Active
- 2017-06-29 CN CN202210686970.6A patent/CN115054586B/zh active Active
- 2017-06-29 WO PCT/US2017/040075 patent/WO2018005849A1/en not_active Ceased
- 2017-06-29 MA MA045547A patent/MA45547A/fr unknown
-
2018
- 2018-12-18 MX MX2022002952A patent/MX2022002952A/es unknown
-
2020
- 2020-10-28 US US17/082,747 patent/US11872229B2/en active Active
-
2023
- 2023-03-17 AU AU2023201685A patent/AU2023201685A1/en not_active Abandoned
- 2023-12-01 US US18/526,225 patent/US12336999B2/en active Active
-
2025
- 2025-05-23 US US19/217,161 patent/US20250381193A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3236943B1 (en) | Compositions for ileo-jejunal drug delivery | |
| CN105848647B (zh) | 包含azd9291的药用组合物 | |
| US20190328672A1 (en) | Solid pharmaceutical compositions and processes for their production | |
| MX2012011022A (es) | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. | |
| WO2010064126A2 (en) | Controlled release dosage forms | |
| WO2015156581A1 (ko) | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 | |
| CN113018273B (zh) | 一种固体制剂及其制备方法和用途 | |
| US11331273B2 (en) | Film-coated tablet having high chemical stability of active ingredient | |
| CN110876732A (zh) | 一种替格瑞洛或其可药用盐的缓释组合物 | |
| WO2019203752A2 (en) | Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| US9561242B2 (en) | Doxycycline composition | |
| EP3796908B1 (en) | Controlled release propiverine formulations | |
| US20190240143A1 (en) | Sustained Release Pharmaceutical Dosage Form of Entecavir | |
| US20200054659A1 (en) | Extended release capecitabine capsules | |
| CN107205947B (zh) | 用于治疗胃肠道疾病的药物组合物 | |
| CN106983729B (zh) | 普拉克索缓释片及制备方法 | |
| WO2013054178A2 (en) | Extended release pharmaceutical compositions containing carmabazepine | |
| JP6303045B1 (ja) | 攪拌造粒法を用いたイミダフェナシンを含有する製剤の製造方法 | |
| US9566287B2 (en) | Pharmaceutical composition of doxycycline with reduced food effect | |
| KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 | |
| NZ789748B2 (en) | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile | |
| US20060257483A1 (en) | Controlled release bupropion dosage forms | |
| WO2026062565A1 (en) | Oral extended-release dosage form of 7- methylxanthine (7-mx) for the treatment of myopia |